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Fecal microbiota transplantation (FMT) is an effective therapy for recurrent Clostridioides
difficile infection (rCDI) and is also considered a potential treatment for a wide range
of intestinal and systemic diseases. FMT corrects the microbial dysbiosis associated
with rCDI, and the engraftment of donor microbiota is likely to play a key role in
treatment efficacy. For disease indications other than rCDI, FMT treatment efficacy
has been moderate. This may be partly due to stronger resilience of resident host
microbiota in patients who do not suffer from rCDI. In rCDI, patients typically have
undergone several antibiotic treatments prior to FMT, depleting the microbiota. In
this study, we addressed the effect of broad-spectrum antibiotics (Ab) as a pre-
treatment to FMT on the engraftment of donor microbiota in recipients. We conducted
a pre-clinical study of FMT between two healthy mouse strains, Balb/c as donors
and C57BL/6 as recipients, to perform FMT within the same species and to mimic
interindividual FMT between human donors and patients. Microbiota composition was
assessed with high-throughput 16S rDNA amplicon sequencing. The microbiota of
Balb/c and C57BL/6 mice differed significantly, which allowed for the assessment of
microbiota transplantation from the donor strain to the recipient. Our results showed that
Ab-treatment depleted microbiota in C57BL/6 recipient mice prior to FMT. The diversity
of microbiota did not recover spontaneously to baseline levels during 8 weeks after
Ab-treatment, but was restored already at 2 weeks in mice receiving FMT. Interestingly,
pre-treatment with antibiotics prior to FMT did not increase the overall similarity of the
recipient’s microbiota to that of the donor’s, as compared with mice receiving FMT
without Ab-treatment. Pre-treatment with Ab improved the establishment of only a few
donor-derived taxa, such as Bifidobacterium, in the recipients, thus having a minor effect
on the engraftment of donor microbiota in FMT. In conclusion, pre-treatment with broad-
spectrum antibiotics did not improve the overall engraftment of donor microbiota, but
did improve the engraftment of specific taxa. These results may inform future therapeutic
studies of FMT.
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INTRODUCTION
Fecal microbiota transplantation is an effective and curative
treatment for rCDI (Mattila et al., 2012; van Nood et al., 2013;
Quraishi et al., 2017), also eliminating rCDI-associated dysbiosis
(Fuentes et al., 2014; Jalanka et al., 2016). Randomized clinical
trials using FMT as a treatment for other intestinal diseases, such
as UC (Narula et al., 2017) or IBS (Xu et al., 2019), have, however,
had moderate or little success. One difference in the treatment
regimens utilizing FMT for rCDI compared with other diseases
is the use of antibiotics. Usually, rCDI patients are treated with
antibiotics (e.g., vancomycin or metronidazole) prior to FMT,
but antibiotics are rarely used before FMT for other indications.
Generally, patients will undergo bowel lavage, provided that FMT
is administered via colonoscopy.
Antibiotics are known to modulate the composition of the
intestinal microbiota in both quantitative and qualitative terms
(Dethlefsen and Relman, 2011; Ianiro et al., 2016), and their
therapeutic efficacy has been demonstrated in non-infectious
diseases such as IBS and hepatic encephalopathy (Ianiro et al.,
2016). In addition to antibiotics, bowel lavage will reduce
the number of intestinal bacteria and affect the microbial
ecosystem temporarily (Morotomi et al., 1989; Jalanka et al.,
2015). Although recent studies have shown that donor microbiota
and specific donor-derived strains colonize the recipient after
FMT (Jalanka et al., 2016; Li et al., 2016; Allegretti et al.,
2019), it remains unclear whether donor strain engraftment is
a prerequisite for the therapeutic efficacy of FMT in rCDI. In
published studies of FMT for both rCDI and UC, similarity
between donor and recipient microbiota profiles was higher in
treatment responders (Moayyedi et al., 2015; Rossen et al., 2015;
Staley et al., 2016), arguing for a critical role of the donor strain
engraftment in treatment efficacy in patients undergoing FMT.
It has been hypothesized that antibiotic pre-conditioning
may lead to a more effective transfer of the donor microbiota
to the recipient, resulting in a higher similarity between
donor and recipient microbiota profiles after FMT. If this
were true, antibiotic pre-conditioning might lead to better
treatment outcomes in patients undergoing FMT. Few previous
experimental studies have also addressed the contribution
of antibiotic pre-treatment before FMT to donor microbiota
engraftment efficacy. Three studies that analyzed the effect of
antibiotics before transplantation of microbiota from human
feces into mice, thus addressing the interspecies transfer,
produced divergent findings, suggesting that broad-spectrum
antibiotics may support microbiota engraftment across the
species barrier (Wos-Oxley et al., 2012; Ji et al., 2017; Staley
et al., 2017). Only two studies analyzed the effects of broad-
spectrum antibiotics before FMT between different strains of the
same mammalian species. In rats, antibiotic pre-treatment did
not improve the engraftment of donor’s microbiota (Manichanh
et al., 2010), whereas in juvenile mice antibiotics in combination
Abbreviations: Ab, antibiotic; ANOVA, analysis of variance; BL, baseline; FMT,
fecal microbiota transplantation; IBS, irritable bowel syndrome; Lav, lavage; PBS,
phosphate-buffered saline; PCoA, principal coordinates analysis; PERMANOVA,
permutational multivariate analysis of variance; rCDI, recurrent Clostridioides
difficile infection; UC, ulcerative colitis.
with bowel lavage enhanced donor microbiota engraftment (Le
Roy et al., 2018). However, this effect appeared to depend mainly
on bowel lavage.
To further test the hypothesis that antibiotic pre-treatment
before the administration of FMT will enhance microbiota
engraftment, we performed an experimental study of FMT
between adult mice from two different inbred strains, Balb/c
as the donor and C57BL/6 as the recipient, mimicking
interindividual differences between human donors and patients.
We compared microbiota changes in recipient mice pre-treated
with a cocktail of broad-spectrum antibiotics (ciprofloxacin,
metronidazole, and vancomycin) and receiving FMT after bowel
lavage with the changes in recipient mice treated with bowel
lavage and FMT, or FMT alone. These results were compared
with those of a group of recipient mice receiving Ab-treatment
and sham FMT, to analyze the compositional changes of recipient
microbiota introduced by antibiotics.
MATERIALS AND METHODS
Mice and Treatments
Four adult Balb/c female mice (FMT donors) were purchased
from Envigo (Madison, WI, United States), maintained under
specific pathogen-free conditions in ventilated/autoclaved cages,
and fed sterilized chow (Teklad Global 16% Rodent Diet 2916C,
Envigo). A colony of C57BL/6 mice (FMT recipients), originally
purchased from The Jackson Laboratory (Bar Harbor, ME,
United States), were maintained in the same facility and under
the same conditions, but in strict isolation from the Balb/c mice.
One week after arrival of the Balb/c mice at the facility, cages were
changed in the evening, and stool pellets were collected from all
four stool donors next morning. The stool material was stored
as described previously (Satokari et al., 2015). Briefly, 500 mg
of stool was suspended in 5 ml of sterile PBS, filtered through
an autoclaved metal sieve, and 5 ml of suspensions containing
10% glycerol were stored at −80◦C until use. Donor mice were
sacrificed after stool sample collection, and coecum and colon
segments were frozen at −80◦C. Two samples of pooled donor
feces were used for microbiota analysis.
Four groups of female C57BL/6 mice, maintained under
the conditions specified above, were matched from 7 litters
(3–5 months old; n = 6–7), following collection of stool samples
from all individuals on day 1 (baseline, BL; collection as above,
Figure 1). On the same day, the drinking water for the two
antibiotic pre-treated groups was supplemented with 660 mg/l
ciprofloxacin (Yliopiston Apteekki, Helsinki, Finland), 1 g/l
metronidazole (Sigma-Aldrich, St. Louis, MO, United States),
and 500 mg/l vancomycin (Orion Pharma, Espoo, Finland).
On day 10, antibiotic treatment was stopped. Stool samples
were collected from all individuals on day 11 (time point pre-
FMT). On the same day, three of the groups were treated
with 200 µl of colonsteril by oral gavage, containing 12 mg
of macrogol 4000, prepared according to the manufacturer’s
instructions (Orion Pharma, Espoo, Finland). Mice from all of
the groups received one injection intraperitoneally of 2.5 mg of
ranitidine hydrochloride in 100 µl volume (GlaxoSmithKline,
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FIGURE 1 | Study design showing the treatment groups of recipient mice. After sampling of feces at baseline (recipients before treatments, BL) from four groups of
mice, two groups of mice were pre-treated for 10 days with an antibiotic cocktail (Ab), consisting of 660 mg/l ciprofloxacin, 1 g/l metronidazole, and 500 mg/l
vancomycin in drinking water. Two groups of mice received fecal microbiota transplantation (FMT) after bowel lavage (lav), one group received FMT without lav, and
one groups received sham FMT with phosphate-buffered saline (PBS) after lav. The time points of fecal (empty bullets) or mucosal (full bullets) samplings are
indicated.
Zeist, Netherlands). Five hours later, 200 µl of pooled, thawed
stool suspension (equal to 20 mg of stool) from Balb/c donor
mice was administered by oral gavage to three groups of mice,
while the remaining sham-FMT group received 200 µl of 10%
glycerol in PBS. On days 25 (time point 2 weeks) and 71 (time
point 8 weeks), stool samples were collected from all individuals
and stored at −80◦C for microbiota analysis. On day 72,
mice were injected with ketamine/xylazine, and exsanguinated
by retroorbital bleeding. Coecum and colon segments were
collected and frozen at −80◦C for microbiota analysis. All
animal procedures were approved by the Southern Finnish State
Administrative Agency (ESAVI/1286/04.10.07/2016).
Fecal Sample DNA Extraction
A previously described, a validated method for fecal sample
microbial DNA extraction was used (Salonen et al., 2010;
Santiago et al., 2014). Repeated bead beating was used as a pre-
treatment, followed by high-throughput DNA extraction using
KingFisher Flex 96 (Thermo Fisher Scientific, Vantaa, Finland).
Extracted DNA was purified with QIAamp DNA Mini-kit
(Qiagen, Hilden, Germany), and concentration measured using
the Quant-iTTM PicoGreenTM dsDNA Assay Kit (InvitrogenTM,
Eugene, OR, United States).
Biopsy DNA Extraction
DNA from the biopsy samples was extracted using a previously
described method (Kalliomäki et al., 2012). In short, enzymatic
lysis and repeated bead beating were used to disrupt microbial
cells. DNA was extracted using the Qiagen DNeasy mini-
spin column (Qiagen, Hilden, Germany), according to the
manufacturer’s instructions for Gram-positive bacteria. DNA
concentration was measured using the Quant-iTTM PicoGreenTM
dsDNA Assay Kit (InvitrogenTM, Eugene, OR, United States).
Microbial DNA Compositional Analysis
Microbial composition in fecal samples was analyzed by
sequencing the hypervariable V3–V4 region of the 16S rRNA
gene with Illumina MiSeq (Klindworth et al., 2013). For the
analysis of mucosal microbiota, full-length 16S rRNA PCR was
conducted first to enrich the microbial DNA in biopsy DNA
samples. Briefly, 1500 bp amplicon was generated by using the
previously designed primers (Wang et al., 2002) and by using the
following amplification conditions: one cycle of 95◦C for 2 min,
followed by 20 cycles of 95◦C for 20 s, 55◦C for 20 s, 72◦C for
90 s, and a final extension cycle of 72◦C for 5 min. PCR products
were purified using the QIAquick R© PCR Purification Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions.
The purified PCR product was used as the template for 16S rRNA
gene V3-V4 region sequencing similarly to the fecal samples by
using the MiSeq platform. The analysis was successful for 102 of
108 fecal samples and for 36 of 54 biopsy samples. The data were
deposited to the European Nucleotide Archive (PRJEB33286).
For processing and analyzing the reads, R package mare
was used (Korpela, 2016). Forward reads trimmed to 150 nt
were used for the analysis. This approach has been previously
observed to produce highly reliable results when using artificial
communities of known composition (Korpela, 2016). To exclude
errors and chimeras, rare reads were eliminated by using a
quality filter for minimal read abundance of 0.001%, and reads
were chimera filtered. After pre-processing, the average read
number was 49,607 per sample (ranging from 6,249 to 335,038,
median 46,629). Taxonomic annotation was made by using the
USEARCH (version 8.1.1756) and SILVA 16S rRNA reference
database version 115 (Quast et al., 2013).
Statistical Methods
For statistical analysis, R package mare was used (Korpela,
2016). It uses tools from R packages vegan (Oksanen et al.,
2019), MASS (Venables and Ripley, 2002), and nlme (Pinheiro
et al., 2019). Genus-level data were used for the statistical
testing. To test differences in the bacterial abundance between
study groups at certain time points, generalized linear mixed
models using the function glm.nb from package MASS
were used. If there was a failure in fulfilling the model
assumptions, alternatively generalized least squares models
were used. The read number for each sample was used
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as an offset. The obtained p-values were corrected using
multiple testing with false discovery rate approach, and FDR-
adjusted p-values (q-values) below 0.05 were considered to
be significant. Principal co-ordinate analysis was used to
visualize microbial composition at different time points and
study groups. The function used utilizes R package vegan and
Bray-Curtis dissimilarities. Moreover, to estimate the grouping
effect on overall microbiota composition, adonis function
(PERMANOVA) in R package vegan was used. Additionally,
ANOVA followed by Tukey’s HSD post hoc test or Student’s
t-test was used for evaluating statistical significance in normally
distributed data. Normality of the data was tested by using the
Shapiro-Wilk test. Similarity between the samples was calculated
with Spearman’s correlation (ρ). OriginPro 2018 (version
b9.5.5.409 Academic) and CorelDRAW (version 20.1.0.708) were
used for visualizing the data.
RESULTS
The main aim of this study was to analyze the effect of antibiotic
pre-treatment on microbiota engraftment after FMT. The study
design is depicted in Figure 1. Briefly, we compared the microbial
changes of the recipient mice pre-treated with antibiotics and
receiving FMT after bowel lavage with the three different control
groups. These included mice that had also received antibiotic pre-
treatment and sham FMT after the lavage, in addition to a group
of mice treated with either bowel lavage and FMT or FMT alone.
Fecal Microbial Populations in Donors
and Recipients Differed at Baseline
At baseline, the fecal microbiota in Balb/c donors differed
significantly from that in C57BL/6 recipients (Figures 2A,B
and Supplementary Figure S1A). The differences between
these mouse strains explained 18% (p = 0.002, PERMANOVA)
of the microbial variation, and the microbiota similarity
between the recipients and donors, measured with Spearman’s
correlation, was on average 0.57 ± 0.03 (SD). At bacteria
phylum level, the differences included higher levels of Firmicutes
and Actinobacteria in donors (62.62 vs. 21.80%, and 9.20 vs.
0.83%, respectively, Figure 2B). Recipient mice had higher
levels of Bacteroidetes and Verrucomicrobia (58.25 vs. 24.72%,
and 14.11 vs. 0.04%, respectively). On average, there were
39.75 ± 2.22 genus-level taxa that had statistically different
abundance (FDR-adjusted p < 0.05) between donors and
recipients (Supplementary Table S1). The observed microbiota
differences between the mouse strains allowed for the assessment
of microbiota engraftment from the donor strain to the recipient
based on microbiota profiling.
Effect of Antibiotic Treatment on
Microbiota Composition
We first assessed the effect of antibiotic treatment on the
microbiota. In addition to the group that later received FMT
after antibiotics pre-treatment (Ab-lav-FMT), a control group
of mice that later received sham FMT was also pre-treated with
antibiotics (Ab-lav-sham). The antibiotic treatment had a strong
effect on microbiota, with 79% of the microbial variation between
the study groups explained by the consumption of antibiotics
(p = 0.01, PERMANOVA, Figure 2C and Supplementary
Figure S1B) at time point pre-FMT. Microbial diversity
was decreased significantly in the antibiotic-treated animals
compared with the untreated animals (p = 9.96 × 10−12,
ANOVA, Tukey’s post hoc, Figure 3A). The diversity did
not recover to baseline levels in the Ab-lav-sham group
during the follow-up period. This was reflected also in the
similarity analysis, where the Ab-lav-sham group showed little
similarity to their own baseline microbiota, both at 2 weeks
(ρ = 0.60 ± 0.08, Figure 3B) and at 8 weeks (ρ = 0.59 ± 0.08,
Figure 3B) after sham FMT.
The microbial composition of animals treated with antibiotics
was significantly reduced after the antibiotic treatment (at
time point pre-FMT), and only 44 of the 117 genera
detected at baseline were present in over 0.01% abundance
(Supplementary Table S2). Here, the most abundant genus-
level taxa were Verrucomicrobium (84.78%), Lactobacillus
(6.70%), uncultured member of Bacteroidetes (2.38%), and
Parabacteroides (1.63%), representing on average 95.49% of all
detected taxa (Supplementary Table S3).
Effect of Antibiotic Pre-treatment on
Microbiota Engraftment
Next, we studied the recovery of antibiotics-depleted microbiota
by FMT, and the differences in donor microbiota engraftment
between the animals that received and those that did not
receive antibiotics before FMT. The dramatic decrease in
microbial diversity caused by the antibiotics was restored by
FMT (Figure 3A). The increase in diversity was detected already
2 weeks after the treatment in the Ab-lav-FMT group, and it
was sustained until the end of the study (Figure 3A). Compared
with the control groups, diversity of the Ab-lav-FMT group was
similar to the mice that were treated with FMT but did not
receive antibiotics (FMT and lav-FMT) (Figure 3A). However,
in the Ab-lav-sham group, diversity remained low at 2 and
8 weeks after sham FMT.
When visualizing compositional dissimilarity with PCoA,
the donor’s microbiota was found to cluster separately from
that of FMT-treated animals. In addition, the samples from
baseline and after FMT were mixed and did not show any
significant shift toward the donor samples (Figure 4A and
Supplementary Figure S1C). This observation was supported
by the similarity analyses showing a higher correlation of the
microbial composition in mice from all FMT groups with their
own baseline (ρ = 0.77, ± 0.02, Figure 3B) than with donors
(ρ = 0.68 ± 0.02, Figure 4B). In this study, the within-animal
similarity in the C57BL/6 mice was 0.89± 0.05.
However, the similarity between donors and recipients
was low at baseline (ρ = 0.57 ± 0.03), and it increased
significantly 2 weeks after FMT in the treated animals (Ab-
lav-FMT: 19.21% increase, p = 2.73 × 10−5; lav-FMT: 9.44%
increase, p = 0.001; FMT group: 12.89% increase, p = 0.0003,
ANOVA, Tukey’s post hoc, Figure 4B). This increase in similarity
was sustained until the end of the study, 8 weeks from
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FIGURE 2 | (A) PCoA of microbiota profiles at bacterial genus level from the study groups at baseline. (B) Fecal microbiota composition in donor and recipient mice
at baseline. Relative abundance scaled to 100%, and number of sequence reads marked with bullets. Within phyla, individual genera are shown with different
shades, and the lightest color shows the combined abundance of the least abundant genera (<0.5% of total). (C) Microbiota composition of donor and recipient
mice at other time points in the study.
FMT (Figure 4B). In contrast, in the Ab-lav-sham group
the similarity to donors decreased from baseline due to the
antibiotic treatment and did not recover in the follow-up
time points at 2 weeks (p = 3.97 × 10−4, ANOVA, Tukey’s
post hoc) and 8 weeks (p = 1.71 × 10−4, ANOVA, Tukey’s
post hoc) after the sham FMT. In addition, the Ab-lav-sham
group separated significantly from other treatment groups in
PCoA analyses at the end of the study concerning both fecal
(p = 0.001, PERMANOVA, Figure 4C and Supplementary
Figure S1D) and mucosal (p = 0.001, PERMANOVA, Figure 4D
and Supplementary Figure S2) microbiota composition. In
summary, FMT restored the microbial diversity disrupted by
antibiotics, but antibiotic pre-treatment did not increase the
overall similarity between donor and recipient microbiota, as
compared with control groups.
Specific Genus-Level Differences in
Microbial Composition After FMT Are
Attributable to Antibiotic Pre-treatment
To assess the magnitude of the changes introduced by
the antibiotic pre-treatment, we determined the number of
significantly differing taxa between the Ab-lav-FMT and other
groups as well as the donors at different time points (Figure 5A).
The obtained FDR-adjusted p-values were calculated using
generalized linear mixed models. At baseline, the donors had the
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FIGURE 3 | (A) Bacterial diversity in different treatment groups across all time points. (B) Similarity between the baseline sample and consecutive samples in all
study groups across all time points.
greatest number (41 of 117 detected) of differing taxa relative
to the Ab-lav-FMT group, which is consistent with the mouse
strain effect. After the antibiotic pre-treatment, the number of
differing taxa increased sharply compared with the animals not
treated with antibiotics. During the follow-up period the Ab-
lav-FMT group remained relatively different from the other
FMT-treated groups (19–32 of the genera showed a statistical
difference), which remained highly similar to each other during
the follow-up period (only 3–4 of the genera showed a statistical
difference between lav-FMT and FMT groups, Supplementary
Figures S3A–C). Throughout the study, the number of taxa
differing between all recipient groups and the donors remained
high (37–62 of the genera, Supplementary Figures S3A–D).
Next, we determined the number of genus-level taxa that
were differentially engrafted in mice pre-treated with antibiotics
compared with the control groups. This was done again by
using a generalized linear mixed model to test the difference
between study groups at both follow-up time points. Two weeks
after FMT, there were 28 significantly different taxa between
the Ab-lav-FMT and lav-FMT groups, and 32 between the
Ab-lav-FMT and FMT groups. Antibiotic pre-treatment had
a substantial effect on the engraftment since there were only
three taxa with significantly different abundance 2 weeks after
FMT between the lav-FMT and FMT groups (Supplementary
Figures S3B,C). Thus, antibiotic pre-treatment had a detectable
effect on the taxa level, but only a minor effect on overall
microbiota engraftment after FMT.
To determine whether the antibiotic pre-treatment improved
the engraftment of specific taxa, we compared the mean relative
abundances of the significantly different taxa in different groups
2 weeks after FMT. Taxa that were detected in the donors but
were absent in the Ab-lav-sham group and were more increased
in group Ab-lav-FMT than in groups lav-FMT or FMT were
deemed to have benefited in their engraftment from antibiotic
pre-treatment. There were five genus-level taxa that matched
these criteria: Bifidobacterium, Adlercreutzia, Enterorhabdus,
Odoribacter, and Alkalibacterium (Supplementary Table S4).
At baseline, the genus Bifidobacterium was present in recipient
mice on average at 0.13% ± 0.001 abundance, and in donors
at 5.72% ± 2.26 abundance (Figure 5B). Two weeks after FMT,
the bifidobacterial abundance in the lav-FMT and FMT groups
remained low (on average 0.34%± 0.002), whereas in the Ab-lav-
FMT group it increased significantly to the level of 2.25%± 0.014
(p = 5.59 × 10−9). In this group, bifidobacterial abundance
remained increased also at 8 weeks after FMT (1.29% ± 0.012,
p = 6.02 × 10−6). Overall, the antibiotic pre-treatment had a
detectable effect on the engraftment of specific genus-level taxa,
most notably on the abundance of Bifidobacterium.
In a similar way, we sought bacterial taxa that were
decreased after FMT in mice pre-treated with antibiotics,
but were present in the other FMT groups on higher level
2 weeks after FMT-treatment. In total, eight genus-level taxa
were significantly less abundant (FDR-adjusted p-value < 0.05;
Supplementary Table S4) in Ab-lav-FMT group than in other
FMT-treated groups. Thus, antibiotic pre-treatment suppressed
some taxa that were not re-introduced by FMT from the other
mice strain. On the other hand, antibiotic treatment as such
increased the relative abundance of three genus-level taxa, and
Marvinbryantia, Stomatobaculum, and an uncultured member of
Firmicutes (incertae sedis) increased in both antibiotic-treated
groups, i.e., groups with and without FMT (Supplementary
Table S4). Interestingly, the abundance of Verrucomicrobium
was increased after the antibiotic pre-treatment (Figure 2C),
was not detected in the donors, and the abundance of this taxa
was decreased in all groups after FMT, but not after sham FMT
(Supplementary Table S4).
Species Richness in Donor and
Recipient Mice
At baseline, donors had significantly higher richness than
recipient mice (p = 1.0 × 10−7, for all group comparisons,
ANOVA, Tukey’s post hoc, Supplementary Figure S4). The
higher richness was transferred with FMT to all treated animals,
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FIGURE 4 | (A) PCoA of fecal microbiota composition: effects of antibiotic pre-treatment and study time point. Ab-lav-sham group is excluded to visualize the
distribution of the FMT group samples in more detail. (B) Microbial similarity to donor for different groups throughout the study. Similarity measured with Spearman
correlation. (C) PCoA of fecal microbiota composition at 8 weeks after (sham) FMT: significant separation of Ab-lav-sham group from the other groups (p = 0.001,
PERMANOVA). (D) PCoA of mucosal microbiota composition at 8 weeks after (sham) FMT: significant effects of antibiotic treatment (p = 0.001, PERMANOVA) and
biopsy location (p = 0.001, PERMANOVA).
where the richness remained high at the follow-up time
points (p < 0.001, ANOVA, Tukey’s post hoc, Supplementary
Figure S4). Thus, significant difference in richness between Ab-
lav-FMT and other FMT-treated groups was not detected 2 or
8 weeks after FMT-treatment (comparison of Ab-lav-FMT and
lav-FMT 2 weeks after FMT-treatment p = 0.99, Ab-lav-FMT
and FMT 2 weeks after FMT-treatment p = 0.98 and comparison
of Ab-lav-FMT and lav-FMT eight weeks after FMT-treatment
p = 0.27, Ab-lav-FMT and FMT 2 weeks after FMT-treatment
p = 0.99, ANOVA, Tukey’s post hoc).
Microbial Composition in Colonic
Mucosa and Length of Colon
At the end of the study, the coecum microbiota of the FMT-
treated mice was composed mainly of Firmicutes (89.50%± 0.83)
and Bacteroidetes (6.08% ± 0.50), whereas microbiota in the
sham-FMT group was dominated by only Firmicutes (96.99%)
(Supplementary Figure S5). Similarly, mainly Firmicutes
and Bacteroidetes were detected in the distal colon of the
FMT-treated animals (82.90% ± 4.51 and 11.93% ± 4.11,
respectively), but in the sham-FMT group the microbiota was
dominated by Firmicutes (68.61%) and Deferribacteres (29.03%)
(Supplementary Figure S5).
In PCoA, mucosal samples from donors and all FMT-treated
animals clustered together, whereas the Ab-lav-sham group
separated from the others (p = 0.001, PERMANOVA, Figure 4D
and Supplementary Figure S2). Moreover, similarity to donor
microbiota was low for the Ab-lav-sham group (Supplementary
Figure S6). In contrast, all of the FMT groups showed high
similarity to donor microbiota (average ρ = 0.78 ± 0.03), but
the highest similarity was observed in the Ab-lav-FMT group
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FIGURE 5 | (A) Number of genus-level bacterial taxa that differed in relative abundance (FDR-adjusted p < 0.05) between the Ab-lav-FMT group versus all other
groups, or versus donor, at four different time points. (B) Relative abundance of genus Bifidobacterium, demonstrating higher levels in Balb/c donor than in C57BL/6
recipient mice. Relative abundance increased in the Ab-lav-FMT group at 2 and 8 weeks after FMT compared with baseline (p = 5.59 × 10−9 and 6.02 × 10−6,
respectively), and also compared with other groups at 2 weeks after FMT (FDR-adjusted p < 0.05). On the other hand, levels of Bifidobacterium were decreased in
the Ab-lav-sham group after antibiotic treatment and remained low until 8 weeks after sham FMT.
(ρ = 0.80 ± 0.02). Thus, colonic microbiota in the FMT groups
resembled those of the donors, whereas the Ab-lav-sham group
had clearly distinct colonic microbiota profiles.
Colon length is known to differ between different mouse
strains and/or colonies, and previous studies have demonstrated
that Balb/c mice have greater colon length than C57BL/6 mice
(Qualls et al., 2006). A comparison of colon length in the
four C57BL/6 recipient groups showed that mice treated with
antibiotics, lavage, and FMT had significantly longer colons than
mice from all other groups combined, resembling the reported
Balb/c donor phenotype (Figure 6, p = 0.02, Student’s t-test).
DISCUSSION
In this study, we assessed the effect of antibiotic pre-treatment on
the engraftment of donor microbiota in FMT. Balb/c mice were
used as FMT donors and C57BL/6 mice as the FMT recipient
strain. At baseline, microbiota composition and richness differed
between donors and recipients. As expected, pre-treatment
with ciprofloxacin, metronidazole, and vancomycin significantly
decreased the bacterial diversity. After FMT, the diversity,
species richness, and similarity to donor microbiota rose in
the Ab-treated group, but the same levels were also reached
in the other FMT groups. Nonetheless, we found effects of
the antibiotic pre-treatment on the engraftment of specific
donor microbiota to recipient mice. Interestingly, abundance
of a number of genus-level taxa, including Bifidobacterium,
was significantly higher in the Ab-treated group 2 weeks
after FMT than in the other study groups. Moreover, colon
length in the Ab-treated group was significantly longer than in
other recipient mice.
Our results demonstrating differences at baseline between
two mouse strains are in line with those observed in an earlier
metagenomic study, which examined five factors, including
FIGURE 6 | Colon length in the four treatment groups (C57BL/6 recipient
mice). Significance level indicated with an asterisk = p < 0.05.
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mouse strain and provider, affecting the composition of the
mouse gut microbiome (Xiao et al., 2015). In another study,
higher richness of donor stool relative to recipient stool was
seen as a positive predictor of microbiota engraftment after FMT
(Ericsson et al., 2017). In our study, donors had significantly
higher richness than recipients, indicating that conditions for
donor microbiota engraftment were favorable. Overall, the
results suggested that higher species richness was transferred
to FMT recipients, but antibiotic pre-treatment offered no
significant benefit.
The antibiotic cocktail (ciprofloxacin, metronidazole, and
vancomycin) used in this study was active against a broad
spectrum of Gram-negative, Gram-positive, and anaerobic
bacteria and was regarded as suitable for clinical application.
As expected, the pre-treatment decreased diversity and reduced
the number of detected taxa. These findings are consistent
with those of Dethlefsen and Relman (2011), who reported a
shift in the distal gut microbial composition and a decrease
of diversity after two courses of ciprofloxacin. In the current
study, at genus level, taxa belonging to Verrucomicrobium,
Lactobacillus, and Parabacteroides dominated the composition
in the recipient mice after pre-treatment with antibiotics.
The genera Lactobacillus and Parabacteroides were detected
in both groups treated with antibiotics until the end of
the study, whereas the abundance of Verrucomicrobium
decreased after FMT in animals treated with antibiotics. Many
Lactobacillus spp. are known to harbor resistance genes
to vancomycin and ciprofloxacin or to have a resistant
phenotype (Campedelli et al., 2019), and members of
the Bacteroides fragilis group, including Parabacteroides
distasonis, are among the anaerobes least susceptible to
antibiotics (Schuetz, 2014). Therefore, it is not surprising
that Lactobacillus and Parabacteroides were found to prevail
after the antibiotic treatment. Verrucomicrobia, on the other
hand, are a special phylum of bacteria that have complex
endomembrane structures and a compartmentalized cell plan
(Lee et al., 2009), which may account for their resistance against
antibiotics. While we are unaware of the traits that conferred
resistance of Verrucomicrobium to the antibiotics applied,
its high abundance in Ab-treated animals indicates effective
mechanisms. Notably, antibiotic resistance of specific bacteria
by deactivation mechanism may give collective resistance
also to other members of the microbial community (Sorg
et al., 2016). Indeed, in addition to the above-mentioned three
taxa, a number of other bacteria were also present in low
amounts in the Ab-treated mice, and these may represent such
co-benefiting taxa.
Although in our study the FMT restored microbial diversity
after antibiotic pre-treatment, the results did not show a
significant increase in overall similarity to donor microbial
composition compared with animals not treated with antibiotics.
Furthermore, the similarity analyses showed a higher correlation
of the microbial composition in mice from all FMT groups with
their own baseline, rather than with the donor communities,
indicating resilience of the host microbiota. Therefore, the
results of this study of FMT between two different inbred
strains of mice did not support the main hypothesis that
antibiotic pre-conditioning will lead to a more effective
transfer of donor microbiota to the recipient as a whole.
Nevertheless, specific taxa were shown to benefit from the
antibiotic pre-treatment.
Here we showed that there were detectable effects on
the abundance of specific bacterial taxa after the FMT.
Five presumably Balb/c donor-derived genus-level taxa,
including Bifidobacterium, were more abundant in the stool
of recipients that had been pre-treated with antibiotics. In
this group, bifidobacterial abundance remained increased
until the end of the study. Since bifidobacteria are non-
pathogenic, generally regarded as safe, and also used as
probiotics, their promotion by antibiotic pre-treatment
may be of interest for FMT, particularly as they are also
known to exert anti-inflammatory and epithelium-reinforcing
actions (Hiippala et al., 2018). Interestingly, a recent study in
humans reported that Bifidobacterium was more abundant
after FMT following pre-treatment with ciprofloxacin,
although this was not compared with FMT without
antibiotic pre-treatment (Kang et al., 2017). Furthermore,
the colon length of mice pre-treated with antibiotics before
FMT was increased at the end of the study relative to all
other groups, indicating that the differences in microbiota
composition may have had physiological effects, affecting the
mouse phenotype.
Previous studies have produced divergent results regarding the
effects of bowel cleansing prior to microbiota engraftment. One
study demonstrated a positive effect of bowel cleansing (Le Roy
et al., 2018), while another study found no impact of lavage alone,
but a combined effect with lavage and antibiotics (Ji et al., 2017).
While our study primarily addressed the effects of antibiotic pre-
treatment on donor microbiota engraftment, group comparisons
suggested no improvement of engraftment by bowel lavage versus
no bowel lavage. However, these results should be interpreted
with caution because we had chosen a lower laxative dose
for mice than the studies mentioned above. In humans, there
is evidence that the effect on microbial composition is larger
when higher amounts of laxative are used (Jalanka et al.,
2015). Also, a recent rodent study showed that a high dose
of purging agent introduced a significant reduction in bacterial
load, resulting in better microbial engraftment (Wrzosek et al.,
2018). Thus, an efficient lavage could provide some advantage
for FMT, and attention should be paid to the lavage regimes
in future studies.
In summary, we showed that in FMT between two
different mice strains, mimicking the clinical settings, pre-
treating the mice with broad-spectrum antibiotics had
only a minor effect on donor microbiota engraftment.
One of the observations was better engraftment of the
genus Bifidobacterium with antibiotic pre-treatment, which
may offer potential benefits in future therapeutic studies.
This was supported by the finding that colon length was
greater in animals pre-treated with antibiotics, thereby
mimicking the donor strain. Since the resilience of the
recipient’s microbiota appeared to limit the engraftment,
a potential use for antibiotics before FMT may be the
modulation of recipient microbiota profiles. Recipient
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microbiota modulation by antibiotic pre-treatment may act
synergistically with donor-derived microbiota in resolving
dysbiosis in human diseases.
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